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Background: Chronic migraine affects 2% of the population. It results in substantial disability and reduced quality
of life. Medications used for prophylaxis in episodic migraine may also work in chronic migraine. The efficacy and
safety of OnabotulinumtoxinA (BOTOX) in adults with chronic migraine was confirmed in the PREEMPT programme.
However, there are few real-life data of its use.
Method: 254 adults with chronic migraine were injected with OnabotulinumtoxinA BOTOX as per PREEMPT
Protocol between July 2010 and May 2013, their headache data were collected using the Hull headache diary and
analysed to look for headache, migraine days decrements, crystal clear days increment in the month post
treatment, we looked at the 50% responder rate as well.
Results: Our prospective analysis shows that OnabotulinumtoxinA, significantly, reduced the number of headache
and migraine days, and increased the number of headache free days. OnabotulinumtoxinA Botox also improved
patients’ quality of life. We believe that these results represent the largest post-marketing cohort of patients treated
with OnabotulinumtoxinA in the real-life clinical setting.
Conclusion: OnabotulinumtoxinA is a valuable addition to current treatment options in patients with chronic
migraine. Our results support findings of PREEMPT study in a large cohort of patients, we believe, is representative
of the patients seen in an average tertiary headache centre. While it can be used as a first line prophylaxis its cost
may restrict its use to more refractory patients who failed three oral preventive treatments.Background
Chronic migraine, defined as headaches on ≥15 days per
month for ≥3 months, of which ≥8 days meet criteria for
migraine without aura or respond to migraine-specific
treatment [1,2], is estimated to affect 2% of the popula-
tion [3,4]. It results in substantial disability and reduced
quality of life (QoL) [5-7] and leads to an increased risk
of anxiety and depression [8].
Chronic migraine has significant health, economic and
social consequences [2,4,9-13]; patients with chronic mi-
graine are more likely to use healthcare resources than
those with episodic migraine (defined as migraine and <15* Correspondence: fayyaz.ahmed@hey.nhs.uk
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in any medium, provided the original work is pheadache days per month) [2], and one in five chronic mi-
graine sufferers cannot work due to the effect of the condi-
tion on their ability to lead a productive life [14]. Chronic
migraine sufferers are also significantly more likely to re-
port depression, anxiety, chronic pain and respiratory dis-
orders than non-chronic migraine sufferers [13].
Medications used for prophylaxis in episodic migraine
may also work in chronic migraine, although only topir-
amate has established evidence [15,16]. However, this
and other unlicensed oral agents have limitations due to
poor tolerability and/or adverse effects, and a considerable
number of patients do not respond [1,17,18]. More inva-
sive and costly options include greater occipital nerve
block (invasive) and occipital nerve stimulation (costly)
that have their own limitations and disadvantages to pa-
tients and the health service [19]. Chronic migraineOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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[6,20-23]. Observational and clinical trials have shown
that 50-80% of patients with chronic migraine overuse
acute medication [24]. As to whether the two are separ-
ate entities or a complication of one another remains
uncertain [25]. For patients who fail on oral therapies,
there is also now the option of treatment with Onabotu-
linumtoxinA before resorting to these invasive and ex-
pensive options.
The efficacy and safety of OnabotulinumtoxinA in adults
with chronic migraine was shown in the phase III Research
Evaluating Migraine Prophylaxis Therapy (PREEMPT)
clinical programme [18,26-29]. These data led to the li-
censing authorities granting approval for this toxin in
chronic migraine. OnabotulinumtoxinA has also more
recently been shown to result in clinically meaningful
reductions in headache impact and improvements in
Health-Related Quality of Life (HRQoL) [30]. Further-
more, recent long-term data have confirmed that most
chronic migraine patients who initially respond to Onabo-
tulinumtoxinA will maintain the response over at least
two years, and a substantial minority will be able to dis-
continue treatment and do well without prophylactic ther-
apy. However, some patients showed reduced response on
repeated injections [31].
Despite being the only drug licensed for prophylaxis in
chronic migraine [28,32], few patients are being offered
OnabotulinumtoxinA due to widespread funding restric-
tions and few data exist in the real-life setting. The aim
of this study was to examine the change in the frequency
of migraine symptoms before and after treatment in the
real-life setting.
Methods
The data was collected in a public sector clinic in the
United Kingdom where patients were treated free of charge
on the National Health Service (NHS) under the guidance
of National Institute of Clinical Excellence (NICE); the or-
ganisation often regarded as a watchdog to determine the
cost-effectiveness of a treatment before recommending
it on the NHS. The funding implications faced in other
countries may be different, although the authors feel
that the NICE recommendations may have impact in
some other countries.
Study participants
Adult patients with chronic migraine (defined according
to the 2004 International Headache Society Criteria) [2]
attending the Hull Migraine Clinic between the first of
July 2010 and the 31st of May 2013 were offered Onabotu-
linumtoxinA after discussion of all available treatment op-
tions, depending on the treatments that they had already
received. The Hull Migraine Clinic (Hull Royal Infirmary
and Spire Hospital Hull and East Riding) is a tertiaryheadache centre that sees 1,200 new headache referrals
each year from across the North of England. Patients seen
towards the start of the study period were either approved
through an Individual Funding Request (IFR) or volun-
teered for the Allergan sponsored training sessions. A
number of these patients had only tried a single preventive
treatment. However, following publication of National In-
stitute for Health and Clinical Excellence (NICE) guidance
in June 2012 [33], subsequent patients included were
treated within the National Health Service (NHS) and
were only given OnabotulinumtoxinA treatment after hav-
ing failed at least three preventive treatments as per NICE
guidance. All patients received free treatment at the point
of entry. Patients had to consent to OnabotulinumtoxinA
treatment according to the PREEMPT study protocol [29].
There was no randomisation in this prospective analysis;
subjects were selected according to their clinical need if
they had chronic migraine that was not satisfactorily
managed by their current therapy. Of note, patients who
fulfilled the criteria for medication overuse were not ex-
cluded since they represent patients in the real-life set-
ting. Due to the high prevalence of medication overuse
in chronic migraine, the IHS has allowed these subjects
to be included in their guidelines for chronic migraine
trials provided that they are stratified accordingly [34].
According to expert opinion, inclusion of medication
overuse patients should be allowed within the classifica-
tion of chronic migraine to accurately reflect the patient
population seen in actual clinical practice [1].
Study design
Subjects were injected intramuscularly with Onabotuli-
numtoxinA according to the PREEMPT protocol, i.e. 155
units injected into 31 injection sites around the head and
neck [29]. The paradigm includes follow the pain injections
of up to further 45 units, although none of our patients re-
ceived additional injections. Patients were asked to main-
tain a headache diary for at least 30 days prior to and
continuously after receiving OnabotulinumtoxinA treat-
ment. The Hull Headache Diary (shown below) (Figure 1)
was used to capture data on headache [35]. The continu-
ous diary filling was mandatory to assess response to treat-
ment in order to determine whether patients were offered
a repeat treatment.
Study measures
From the completed patient diaries, assessments were
made of headache days, migraine days and headache-
free days; also, of analgesic medication use, triptan use,
adverse events and days off work (if applicable). Quality
of life was also measured through the Headache Impact
Test (HIT-6) in patients receiving injections after the NICE
guidance was published. For purpose of repeat treatment
we used the responder criteria defined by NICE i.e. at least
Figure 1 Hull headache diary.
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marked reduction in migraine days than headache days we
devised our own responder criteria (Hull Criteria) for ana-
lysing prospective patients in this study. A responder was
defined as one with a 50% reduction in headache or mi-
graine days, or an increment in headache free days twice
that of the baseline in a 30-day period. Those with less
than three headache free days were only classed as a re-
sponder if they achieved a minimum of six headache free
days after the treatment. Some patients who failed all three
parameters could still receive another Onabotulinumtox-
inA injection if they perceived that the first injection had
improved their QoL based on the patient’s perception or
improvement on at least six points on the HIT-6 score, al-
though as they did not fulfil the NICE responder criteria,
further funding applications were made on exceptional
grounds. A 50% and 75% response for each of the parame-
ters, and those fulfilling two or all the three above parame-
ters, were also analysed.
Statistical analysis
The primary aim of the analysis was to compare the dif-
ference between outcome measurements made beforeand after treatment. All outcomes were measured on a
continuous scale.
A statistical examination of the distribution of these out-
comes found that they were skewed in their distribution
for each set of measurements, and in terms of the change
in values from pre- to post-treatment. As a result of these
skewed distributions, the Wilcoxon matched-pairs test
was used to compare the change in values over time.
For each patient, it was calculated whether they were a
‘responder’ based on either a 50% or 75% reduction in
the number of days with symptoms. The exception was
for headache free days where a responder was defined
by either a two- or three-fold increase in the number of
crystal clear days, provided there were at least three
headache free days prior to treatment. P- Values of less
than 0.05 were regarded as evidence of a statistically sig-
nificant result.
HIT-6 was used to quantify the change in QoL. The
HIT-6 score was analysed on a continuous scale, and an
examination of the change in values over time indicated
that the changes were normally distributed. As a result,
the paired t-test was used to compare theHIT-6 values
on the two occasions.
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Demographic and baseline headache characteristics
A total of 455 treatment cycles were given in all; of 284
patients injected, full data were available on 254 patients
(55 male, mean age 48.6 years; range 19–77 years, 199 fe-
male (78% of cohort), mean age 44.06 years, range 19–91
years). Patients had the diagnosis of chronic migraine for
a mean of 1.4 years (range ten months to three years) and
reported daily headaches for a mean of 8.8 years (range
18 months to 30 years).
Prior prophylactic treatments
Of the 254 patients, 240 (94.4%) had received (and failed
due to lack of efficacy or intolerable side effects) three
or more preventative treatments prior to Onabotulinum-
toxinA; twelve patients (4.7%) had received two preventa-
tive drugs, and two patients (0.7%) had received one
preventative treatment and opted by choice for Onabotuli-
numtoxinA treatment. Note that patients who received
OnabotulinumtoxinA following failure to respond to one
or two preventative treatments were given the treatment
before NICE guidance was published.
Acute analgesics overuse
Full data on acute analgesic use were available on 242 pa-
tients, of whom 122 (50.4%) fulfilled the criteria for misus-
ing painkillers and/or triptans as per The International
Classification of Headache Disorders [2] definition.
Efficacy results
A comparison of all pre- and post-treatment outcomes
is shown in Table 1. As the outcomes were skewed in
their distribution, the median and inter-quartile ranges
(IQR) were used to summarise the responses at each
time-point. The median change over time, correspond-
ing confidence interval (CI) and p-values are also
reported.
Graphical illustrations of key pre- and post-treatment
results are shown in Figures 2, 3, 4 and 5.Table 1 Change in outcomes pre- to post-treatment
Outcome n Pre-treatment Median (IQR) Post-t
Headache days 254 27 (22, 30)
Migraine days 254 15 (10, 19)
Crystal clear days 254 3 (0, 8)
Mild days 254 10 (7, 15)
Painkiller days 242 12 (7 ,20)
Triptan days 241 5 (0, 8)
Days off work 58 4 (3, 6)
The analysis suggested statistically significant differences between the pre-and pos
migraine days, mild days, painkiller days, triptan days and days off work were all fo
example, the median number of headache days was 27 before treatment reduced t
the number of headache free days from pre- to post-treatment (3 to 12 days respeThe 50% or 75% reduction data (and ≥2 and ≥3-fold
increase in crystal clear days) are summarised in Table 2.
Of the cohort, 80/254 (32%) reported at least a 50%
reduction in headache days, 128/254 (50%) reported at
least a 50% reduction in migraine days and 128/254
(50%) reported at least an increase in headache free days
twice that of baseline. Also, 66 out of 254 (26%) re-
ported an improvement in all three parameters, 106
(42%) in at least two of the three parameters and 167
(65.7%) in at least one of the three parameters. Of the
cohort, 36/254 (14%) reported at least a 75% reduction
in headache days, 58/254 (24%) reported at least a 75%
reduction in migraine days and 79/254 (31%) reported
at least an increase in crystal clear days three times that
of baseline. Also, twenty out of 254 (7.8%) reported an
improvement in all three parameters, 47 (18.5%) in at
least two of the three parameters and 107 (42%) in at
least one of the three parameters.
Responders as per study criteria
As per the study criteria, responders were defined as hav-
ing a 50% reduction in headache or migraine days or an
increment in headache free days twice that of the baseline
in a 30-day period.
From this, the following responder criteria were
achieved:
 87 patients (34%) met none of the criteria
 61 patients (24%) met only one of the three criteria
 40 patients (16%) met two of the three criteria
 66 patients (26%) meet all three criteria.
Using Hull criteria, the authors found nearly two
thirds of patients showed a meaningful response. The
reduction in headache days was 32% compared to the
reduction in migraine days (50%) or an increment in
headache free days twice the baseline (50%). Evaluation
of migraine and headache free days were, therefore,
more sensitive in assessing response than headache
days.reatment Median (IQR) Change Median (95% CI) p-value
18 (10, 25) −7 (−8, −5) <0.001
7 (3, 12) −6 (−8, −5) <0.001
12 (5, 20) 7 (5, 8) <0.001
8 (4, 13) −1 (−2, −1) <0.001
6 (2, 12) −3 (−4, −3) <0.001
2 (0, 6) 0 (−1, 0) <0.001
1 (0, 4) 2 (3, 1) <0.001
t- treatment measurements for all outcomes examined. Headache days,
und to be significantly reduced after compared with before treatment. For
o 18 after treatment (p < 0.001). Conversely, there was a significant increase in
ctively) (p < 0.001).
Figure 2 Change in headache days pre- and post-BOTOX in
chronic migraine sufferers*. *In this box plot, the middle line is
the median. The ‘box’ part represents the inter-quartile range (IQR),
i.e. the middle half of the data. The ‘whiskers’ (i.e. the lines that come
out from the box) then typically represent the minimum to max-
imum points. The exception is for points that are more than 1.5
times the IQR away from the box, in which case these are plotted
separately. The value of 1.5 IQRs is chosen by convention
in statistics.
Figure 4 Change in crystal-clear days pre- and post-BOTOX in
chronic migraine sufferers.
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There were 3,855 moderate to severe headache days
pre-OnabotulinumtoxinA treatment. Post- treatment,
the number of moderate to severe headache days were
reduced to 2,164 (−44%).
There were 2,645 mild days pre- OnabotulinumtoxinA
treatment; of these, 2,234 (−16%) remained mild after
treatment. There were 1,131 crystal clear days pre- Ona-
botulinumtoxinA treatment and 2,502 post- Onabotuli-
numtoxinA treatments.
Productivity
Data on overall days off work was available for 58/254
patients (23%); in these, the median number of days offFigure 3 Change in migraine days pre- and post-BOTOX in
chronic migraine sufferers.work per month reduced from 3.5 to 1 days after Ona-
botulinumtoxinA (Table 1) (Figure 6). Furthermore, 53%
achieved ≥50% reduction - and 29% achieved ≥75% re-
duction in days off work (Table 2).
Safety and tolerability
Of the 254 patients (with all patients given the PRE-
EMPT paradigm of 155 units injected into 31 sites), the
following adverse events were observed (Table 3).
Impact on quality of life
Full HIT-6 scores were available for 177/254 patients
(69.9%) in the cohort. The mean and standard deviation
score at each time point is shown in Table 4, along with
the mean change over time, the corresponding confi-
dence interval (CI) and the p-value. There was a mean
reduction of almost 10 units in the HIT-6 score from
pre- to post-treatment (p < 0.001). A graphical illustra-
tion of the before and after treatment scores is shown in
Figure 7.Figure 5 Change in days taking painkillers pre- and post-BOTOX
in chronic migraine sufferers + .
Table 2 The number of patients who achieved a ≥50%
or ≥75% reduction in outcome measures following
BOTOX treatment
Outcome ≥50% reduction n (%) ≥75% reduction n (%)
Headache days 80/254 (32%) 36/254 (14%)
Migraine days 128/254 (50%) 58/254 (24%)
Mild days 70/254 (28%) 32/254 (13%)
Painkiller days 87/243 (36%) 47/243 (19%)
Triptan days 76/242 (31%) 36/242 (15%)
Days off work 30/58 (53%) 19/58 (29%)
≥2-fold increase n (%) ≥3-fold increase n (%)
Crystal clear days 128/254 (50%) 79/254 (31%)
Table 3 Adverse events
Adverse event observed Number of
patients/254 (%)
Pain at the site of injection for at least 24 hours 38 (14.9)
Neck Stiffness 37 (14.56)
Ptosis 28 (11)
Reported but did not complain of inability to frown 15 (5.9)
Exacerbation of headache for five days 11 (4.3)
Difficulty in swallowing 5 (1.96)
Fainting during injection 3 (1.2)
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This prospective analysis has shown that, in a real-life
clinical setting, OnabotulinumtoxinA can effectively re-
duce headache days and migraine days by at least 50%,
and increase headache free days from baseline in chronic
migraine sufferers. OnabotulinumtoxinA use also resulted
in increased work productivity. The percentage of patients
who achieved at least a 50% reduction in headache days
and migraine days were 32% and 50% respectively; the
percentage of patients who achieved at least a 75% reduc-
tion in headache days and migraine days were 14% and
24% respectively. Furthermore, 50% of patients achieved
at least a 50% increment in headache free days twice that
of the baseline in a 30-day period, and 31% achieved at
least a 75% increment in crystal clear days three times the
baseline in a 30-day period.
This analysis introduces the Hull criteria for responders
as a tool to evaluate response to OnabotulinumtoxinA. It
includes headache days, migraine days and headache free
days due to the importance of considering severity of
headache as well as frequency. The authors noticed thatFigure 6 Change in days off work pre- and post-BOTOX in
chronic migraine sufferers.patients with mild headache days often reported as head-
ache free unless they were prompted with the term ‘crystal
clear’. We propose to use the term ‘crystal clear’ in estab-
lishing true headache free days. Our data showed a reduc-
tion in headache days (32%) less than migraine days (50%)
or increment in headache free days twice the baseline
(50%). NICE guidance [32] used a 30% reduction in
headache days as its only criteria to define a meaningful
response to OnabotulinumtoxinA. However, from ex-
tensive experience, the authors believe that evaluation
of headache severity through migraine days is a more
valuable measure of efficacy in clinical practice. The au-
thors propose that NICE revisits its definition of a re-
sponder. However, applying the NICE criteria of 30%
reduction (rather than 50% used in the Hull criteria), the
responder rate for headache days in this analysis increased
from 32% to 46.5%.
Our study provides the first large prospective data on
patients treated with OnabotulinumtoxinA in a real
life clinical setting since the publication of PREEMPT.
The PREEMPT 56-week clinical trial programme was
the largest clinical programme investigating the use of
OnabotulinumtoxinA as a prophylactic treatment for
chronic migraine using a defined set of diagnostic cri-
teria and defined clinically relevant outcome measures.
The pooled analysis of the entire 56-week PREEMPT
clinical programme supports the safety and efficacy of
OnabotulinumtoxinA for the prophylactic treatment of
chronic migraine. Statistically significant reductions were
observed for OnabotulinumtoxinA vs. placebo for the pri-
mary efficacy variable of headache day frequency at week
56, as well as change from baseline in mean migraine days,
moderate/severe headache days, and total cumulative
hours of headache on headache days. Furthermore, there











HIT6 score 177 68.9 (4.3) 59.2 (8.2) −9.7 (−11.0, −8.4) <0.001
Figure 7 Change in HIT-6 score before and after treatment
with BOTOX.
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intake favouring OnabotulinumtoxinA versus placebo at
week 24 and statistically significant improvements from
baseline at week 56 [18].
Our data supports the results and outcome from PRE-
EMPT, although in some aspects our population was
different to PREEMPT patients. In our study, 94.4% of pa-
tients had received three or more preventative treatments
prior to OnabotulinumtoxinA. In the PREEMPT study,
35% of patients failed three oral therapies and 65% failed
one oral therapy, suggesting a more severely affected
population in our cohort. Furthermore, the number of
headache days before receiving treatment was higher in
this analysis [27] compared with the PREEMPT study
(19.9 days in OnabotulinumtoxinA group in pooled ana-
lysis) [25], also suggesting a more severely affected popula-
tion. However, only 50% of patients in this cohort fulfilled
the criteria for medication overuse compared to 67% in
the PREEMPT study. OnabotulinumtoxinA related ad-
verse events were extremely low in this analysis, and no
newly emerging safety signals were noted, although pain
at the site of injection and neck stiffness was reported in
significantly more patients than in the PREEMPT. The
relatively low rate of adverse events is consistent with
known tolerability profile of OnabotulinumtoxinA, and
with results from the PREEMPT study.
Although this analysis is only subjective according to
patient diaries, the HIT-6 results suggest an improved
quality of life for chronic migraine patients using Ona-
botulinumtoxinA who often suffer pain, disability and
anxiety from their symptoms. In addition, the improved
productivity (assessed by reduced days off work) further
supports this suggestion.
Patients with chronic migraine represent a treatment
challenge [1,17,23], and are an important clinical, social
and financial burden [4,12,13,36-38]. One analysis showed
that, although the direct costs of migraine are high, 70-90%of the total cost of migraine is generally as a result of in-
direct costs [39]. Oral therapies traditionally used in
chronic migraine are associated with limitations, e.g.
lack of evidence base to support their use, adverse events
and contraindications. Apart from OnabotulinumtoxinA,
only topiramate (licensed for both episodic and chronic
migraine) is supported by randomised, double-blind,
placebo-controlled trial data [15,16]. From the authors’
clinical experience seeing hundreds of patients with
chronic migraine in the specialist clinic, the authors
feel that OnabotulinumtoxinA should be given after
first-line treatments (e.g. tricyclic antidepressants, beta-
blockers and topiramate) have been tried and failed,
and before some other preventive treatments, such as
sodium valproate, methysergide, and greater occipital
nerve block/nerve stimulation. The authors feel that the
responder rate observed in PREEMPT and this analysis
justifies this position for OnabotulinumtoxinA in the
care pathway. OnabotulinumtoxinA may well be pre-
ferred as a first choice prophylaxis in chronic migraine
although authors feel its cost may well hinder its use as
a first line.
In terms of how representative the patient cohort in
this analysis is to clinical practice, from the authors’ ex-
perience, it is felt that this cohort is representative of
patients seen in an average tertiary headache centre. For
this reason, it can be projected that clinicians in other
centres could observe similar benefits from using Ona-
botulinumtoxinA in their chronic migraine patients who
fail oral prophylactic therapies.
Concerning study limitations, a well-known effect in
migraine studies is the high placebo response rate. Fur-
thermore, parenteral procedures are additionally associ-
ated with increased placebo response rates [40]. Clearly,
this cannot be assessed in this analysis. Furthermore, the
absence of an active comparator precludes comparison
of the efficacy of OnabotulinumtoxinA with other ther-
apies. However, patients included in this analysis had
failed other traditional treatment options (at least one),
were suffering from a considerable number of headache
and migraine days and were heavily overusing acute
pain medications. All of these measures improved with
OnabotulinumtoxinA.
The authors do not have a comparison between those
who tried one versus two versus three or more preventive
treatments prior to OnabotulinumtoxinA but such an
analysis will be performed as these data will become avail-
able. The authors also do not have data as to whether
there is correlation between the number of headache days
prior to treatment and response to OnabotulinumtoxinA.
There is no doubt that patient expectations play an im-
portant role in determining whether a given treatment is
effective. However, in the authors’ experience, no differ-
ence was observed between those who were treated in
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given treatment on the NHS.
The long-term outcome of patients treated with Onabo-
tulinumtoxinA remains unclear. The only data available is
from Rothrock et al., where 68% of patients continued to
receive treatment after two years, although these patients
were receiving treatment through insurance reimburse-
ment and criteria for the continuation of treatment
remains unclear [31]. The authors intend to see the out-
come in this patient cohort where treatment is largely
funded through the NHS based on NICE guidance where
treatment must stop once the migraine becomes episodic.
Implications in the United Kingdom (UK)
The healthcare system (NHS) in the UK offers free treat-
ment at the point of entry. However, expensive treatments
such as OnabotulinumtoxinA are subject to approval by
the NICE who evaluates the cost effectiveness and the
gain in Quality Adjusted Life Year (QALY) of a treatment
before recommending it. Patients with chronic migraine
often suffer for many years and either stays in the health-
care system or return periodically. In the current health
care environment, costs of treatment as well as costs of a
particular condition (direct and indirect) must, of course,
be an important consideration. The UK’s NICE - now a
globally considered monitor of cost-effectiveness - ap-
proved the use of OnabotulinumtoxinA in chronic mi-
graine in 2012, indicating that it is considered to be a
cost-effective option in eligible chronic migraine sufferers
[33]. It can be calculated that, overall, relatively few
patients with chronic migraine would be eligible for Ona-
botulinumtoxinA. Such a calculation needs to take into
account the total adult population, the estimated preva-
lence of chronic migraine (1.8%) [3], and the fact that only
around 20% of patients with chronic migraine receive a
formal diagnosis [6]. Of sufferers, those who have failed
three preventive treatments would be around one third
of this number [26-28] and around 50% of chronic mi-
graine patients respond to OnabotulinumtoxinA treat-
ment [26,41]. Consequently, the budget impact will be
small, particularly compared with the cost of wasted
medications, repeat consultations, hospitalisations and the
use of greater occipital nerve block or occipital nerve
stimulation in these patients.
The significant improvement in work productivity with
OnabotulinumtoxinA must also be considered an add-
itional important finding for commissioners of health.
Costs lost to reduced work productivity from chronic
migraine are considerable, with 50% of chronic migraine
sufferers losing ≥2 hours/week in the previous two weeks
of their total productive time in one study [42]. Further-
more, over a three month period, chronic migraine has
been shown to significantly reduce activities of daily living,
for example, ability to perform household work andparticipate in family activities [6]. In both the PREEMPT
study and in this analysis, OnabotulinumtoxinA was
shown to improve productivity.
The authors acknowledge that the data reported here
are a snapshot of a group of patients, and that there is a
need for a more robust study which is now far more
possible due to the recent NICE approval.
Conclusions
OnabotulinumtoxinA is a valuable addition to current
treatment options in patients with chronic migraine re-
fractory to or intolerant of traditional oral prophylactic
therapies. In this prospective analysis of 254 patients,
OnabotulinumtoxinA significantly reduced the number
of headache and migraine days, and significantly increased
the number of headache free (crystal clear) days. It also
improved patient’s quality of life. While the cost of Ona-
botulinumtoxinA may prevent its use as a first line treat-
ment we concur the NICE view that it should be offered
to patients who do not gain benefit from three oral
prophylactic agents and before less favourable oral agents
(Epilim, Methysergide) and invasive options of greater
occipital nerve block/occipital nerve stimulation. This
will also help to avoid overuse of other analgesics, in-
cluding triptans.
Clinical implications or article highlights
In this prospective analysis of 254 patients in a real-life
setting of a tertiary headache clinic, Onabotulinumtox-
inA significantly reduced the number of headache and
migraine days, and significantly increased the number of
crystal clear days. It also improved patient’s quality of
life. It is believed that these results represent data on the
largest post-marketing cohort of patients treated with
OnabotulinumtoxinA in the real-life clinical setting. Pa-
tients who do not gain benefit from three oral prophylactic
agents should be offered OnabotulinumtoxinA before the
use of costly and invasive options, such as greater occipital
nerve block/occipital nerve stimulation. This will also help
to avoid overuse of other analgesics, including triptans.
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